文献速递神经肌肉病

德国注册研究中LRP4抗体阳性重症肌无力的表型、严重程度与治疗

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.
PubMed 文献 · Neurology · 2026-07-06

基于德国前瞻性纵向MG注册研究,对1432例完成LRP4、AChR和MuSK抗体检测的患者分析显示,4.8%为LRP4抗体阳性(其中2.4%为单阳性,2.4%为LRP4/AChR双阳性)。LRP4单阳性患者症状发生率高,升级治疗(如利妥昔单抗)和挽救治疗(如IVIG)使用率高,疾病负担评分显著高于其他亚组;而LRP4/AChR双阳性患者的负担和治疗模式与其他亚组相当。

要点

  • LRP4单阳性MG是独立表型,疾病负担重且治疗需求高。
  • LRP4单阳性患者使用利妥昔单抗和IVIG等升级/挽救治疗的比例高。
  • LRP4/AChR双阳性MG的疾病负担和治疗模式与其他MG亚组相近。

核心结论

  • LRP4抗体单阳性MG代表一种以高疾病负担和高治疗需求为特征的独立表型。
  • LRP4/AChR抗体双阳性MG的表型更接近其他MG亚组。

研究设计与样本

  • 前瞻性纵向德国MG注册研究,纳入3319例患者,其中1432例(43.1%)完成LRP4、AChR和MuSK抗体检测。

主要发现

  • 在1432例完成抗体检测的患者中,4.8%为LRP4抗体阳性(2.4%单阳性,2.4%双阳性),63.6%为AChR抗体阳性,2.4%为MuSK抗体阳性,0.8%为MuSK/AChR双阳性,28.4%为三重血清阴性。
  • LRP4单阳性患者症状发生率高,所有LRP4抗体阳性患者升级治疗(如利妥昔单抗)和挽救治疗(如IVIG)使用率高。
  • 线性混合效应模型显示,LRP4单阳性患者疾病负担高于所有其他亚组,例如与AChR抗体阳性相比,MG-ADL差值为-2.5分(95% CI -3.9至-1.2),MG-Qol15r差值为-8.4(95% CI -13.3至-3.4)。
  • LRP4/AChR双阳性患者的疾病负担和治疗模式与其他亚组相当。

关键数值与推荐

  • LRP4抗体单阳性患者相比AChR抗体阳性患者,MG-ADL评分差异为-2.5分(95% CI -3.9至-1.2)。
  • LRP4抗体单阳性患者相比AChR抗体阳性患者,MG-Qol15r评分差异为-8.4(95% CI -13.3至-3.4)。

临床怎么用

  • 对LRP4抗体单阳性MG患者应认识到其高疾病负担,可能需要更积极的升级治疗(如利妥昔单抗)和挽救治疗(如IVIG)。
  • LRP4/AChR双阳性MG患者的治疗策略可参考其他MG亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lipoprotein receptor-related protein 4 antibody-positive myasthenia gravis (LRP4-Ab-positive MG) is a rare serologic subgroup with poorly defined clinical phenotype. This study investigated demographics, clinical features, treatments, and disease burden of LRP4-Ab-positive MG against other antibody-defined subgroups. METHODS: Patients from the prospective longitudinal German MG registry tested for LRP4, AChR, and MuSK Abs were grouped and analyzed for symptoms, treatment, and disease burden scores (for example, Myasthenia Gravis Activities of Daily Living [MG-ADL] and Myasthenia Gravis Quality-of-Life 15-item revised version scale [MG-Qol15r]). RESULTS: Among 3,319 patients, 1,432 (43.1%, median age 54, 57.4% female) had complete antibody testing: 4.8% of these were LRP4-Ab-positive (2.4% single-positive; 2.4% LRP4/AChR-Ab-double-positive), 63.6% AChR-Ab-positive, 2.4% MuSK-Ab-positive, 0.8% MuSK/AChR-Ab-double-positive, and 28.4% triple seronegative. LRP4-Ab-single-positive patients reported high symptom rates, and all LRP4-Ab-positive patients showed high rates of escalation (e.g., rituximab) and rescue therapies (e.g., IVIG). Linear mixed-effects models revealed greater disease burden in LRP4-Ab-single-positive patients vs all other subgroups (e.g., vs AChrR-Ab-positive: MG-ADL -2.5 points [95% CI -3.9 to -1.2]; MG-Qol15r -8.4 [95% CI -13.3 to -3.4]). Conversely, LRP4/AChR-Ab-double-positive patients showed burden and treatment patterns comparable with other subgroups. DISCUSSION: LRP4-Ab-single-positive MG represents a distinct phenotype characterized by high disease burden and treatment needs. By contrast, LRP4/AChR-Ab-double-positive MG phenotypes align more closely with other MG subgroups. TRIAL REGISTRATION INFORMATION: German clinical trial registry (drks.de), DRKS00024099, first patient enrolled: February 4, 2019.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Preßler H, Stascheit F, Aigner A, et al. Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry. Neurology. 2026. PMID: 42407020. doi:10.1212/WNL.0000000000218308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。